Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements about acyclovir/valacyclovir and prescribing-label contraindications align with the provided label excerpts, but multiple statements about brand naming and general product equivalence are not supported by the provided FDA label text.
Category Scores
Accurate Statements
If the active ingredient on the label is listed as acyclovir, the medication is the same drug even if the brand name differs by manufacturer.
Not supported by the provided label excerpts (no statement about brand equivalence).
Valacyclovir is a different prodrug that converts to acyclovir in the body.
Supported indirectly by the contraindication statement referencing both acyclovir and valacyclovir ("Acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir"). The provided excerpts do not explicitly state “prodrug converts to acyclovir,” so this conversion detail is not directly supported.
Unsupported Statements
Acyclovir is sold under several brand names depending on the country and the exact formulation.
No brand-naming information is present in the provided label excerpts.
A commonly known brand name for acyclovir is Zovirax.
No brand names (including Zovirax) are present in the provided label excerpts.
If the active ingredient on the label is listed as acyclovir, the medication is the same drug even if the brand name differs by manufacturer.
No statement in the provided label excerpts addresses brand-to-ingredient equivalence or interchangeability.
Some products contain valacyclovir.
The provided excerpts mention valacyclovir only in the contraindication hypersensitivity wording; they do not state that products contain valacyclovir in general.
Valacyclovir is a different prodrug that converts to acyclovir in the body.
While valacyclovir is mentioned in the contraindication text, the provided excerpts do not explicitly describe valacyclovir as a prodrug or state conversion to acyclovir.
Contradictions
Important Omissions
No dosage/administration, renal adjustment, contraindication context, warnings (e.g., renal failure; TTP/HUS), or adverse reaction information was actually evaluated against the label because the provided statements are not specific to these sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Brand/equivalence and valacyclovir-prodrug conversion assertions are not supported by the provided label excerpts; if used for decision-making, these could lead to misinterpretation of product identity or pharmacologic expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Brand-naming and brand-to-ingredient equivalence claims are not present in the supplied label excerpts; valacyclovir prodrug-to-acyclovir conversion is not explicitly supported.
Suggested Improvement
Limit statements to what the provided label excerpts support (e.g., hypersensitivity contraindication referencing both acyclovir and valacyclovir) and remove or qualify unsupported brand and conversion claims unless additional label text is provided that explicitly addresses them.